Laekna Therapeutics closes $18.5mm Series A round
Laekna Therapeutics Shanghai Co. Ltd. (developing both small-molecule and antibody-targeted drugs for cancer and liver diseases) raised $18.5mm through a Series A round led by OrbiMed Asia, with AnlongMed also participating. The 2016 start-up plans to use the funding to progress its pipeline. Laekna currently has three oncology candidates, including Phase II LAE001 (CFG920), an oral CYP17 inhibitor for prostate cancer, in-licensed from Novartis last year. It is also developing compounds for liver diseases, including NASH and hepatic cirrhosis.
- Large Molecule
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.